|
1
|
Liu Y, Ao X, Jia Z, Bai XY, Xu Z, Hu G,
Jiang X, Chen M and Wu H: FOXK2 transcription factor suppresses
ERalpha-positive breast cancer cell growth through down-regulating
the stability of ERα via mechanism involving BRCA1/BARD1. Sci Rep.
5(8796)2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang M, Zhao F, Li S, Chang AK, Jia Z,
Chen Y, Xu F, Pan H and Wu H: AIB1 cooperates with ERα to promote
epithelial mesenchymal transition in breast cancer through SNAI1
activation. PLoS One. 8(e65556)2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ao X, Li S, Xu Z, Yang Y, Chen M, Jiang X
and Wu H: Sumoylation of TCF21 downregulates the transcriptional
activity of estrogen receptor-alpha. Oncotarget. 7:26220–26234.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mattiuzzi C and Lippi G: Current cancer
epidemiology. J Epidemiol Glob Health. 9:217–222. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kang SY, Kim YS, Kim Z, Kim HY, Lee SK,
Jung KW and Youn HJ: Korean Breast Cancer Society: Basic findings
regarding breast cancer in Korea in 2015: Data from a breast cancer
registry. J Breast Cancer. 21:1–10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Drukteinis JS, Mooney BP, Flowers CI and
Gatenby RA: Beyond mammography: New frontiers in breast cancer
screening. Am J Med. 126:472–479. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu Y, Ao X, Ding W, Ponnusamy M, Wu W,
Hao X, Yu W, Wang Y, Li P and Wang J: Critical role of FOXO3a in
carcinogenesis. Mol Cancer. 17(104)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Capellini TD, Zappavigna V and Selleri L:
Pbx homeodomain proteins: TALEnted regulators of limb patterning
and outgrowth. Dev Dyn. 240:1063–1086. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Welsh IC, Hart J, Brown JM, Hansen K,
Rocha Marques M, Aho RJ, Grishina I, Hurtado R, Herzlinger D,
Ferretti E, et al: Pbx loss in cranial neural crest, unlike in
epithelium, results in cleft palate only and a broader midface. J
Anat. 233:222–242. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Longobardi E, Penkov D, Mateos D, De
Florian G, Torres M and Blasi F: Biochemistry of the tale
transcription factors PREP, MEIS, and PBX in vertebrates. Dev Dyn.
243:59–75. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Nourse J, Mellentin JD, Galili N,
Wilkinson J, Stanbridge E, Smith SD and Cleary ML: Chromosomal
translocation t(1;19) results in synthesis of a homeobox fusion
mRNA that codes for a potential chimeric transcription factor.
Cell. 60:535–545. 1990.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Monica K, Galili N, Nourse J, Saltman D
and Cleary ML: PBX2 and PBX3, new homeobox genes with extensive
homology to the human proto-oncogene PBX1. Mol Cell Biol.
11:6149–6157. 1991.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pöpperl H, Rikhof H, Chang H, Haffter P,
Kimmel CB and Moens CB: Lazarus is a novel pbx gene that globally
mediates hox gene function in zebrafish. Mol Cell. 6:255–267.
2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Heidet L, Moriniére V, Henry C, De Tomasi
L, Reilly ML, Humbert C, Alibeu O, Fourrage C, Bole-Feysot C,
Nitschké P, et al: Targeted exome sequencing identifies PBX1 as
involved in monogenic congenital anomalies of the Kidney and
urinary tract. J Am Soc Nephrol. 28:2901–2914. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Villaescusa JC, Li B, Toledo EM, Rivetti
di Val Cervo P, Yang S, Stott SR, Kaiser K, Islam S, Gyllborg D,
Laguna-Goya R, et al: A PBX1 transcriptional network controls
dopaminergic neuron development and is impaired in Parkinson's
disease. EMBO J. 35:1963–1978. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yu B, Tian X, Zhang L and Feng R:
Hematopoietic PBX-interaction protein promotes breast cancer
sensitivity to paclitaxel through a microtubule-dependent
mechanism. DNA Cell Biol. 35:740–745. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ma YY, Zhang Y, Mou XZ, Liu ZC, Ru GQ and
Li E: High level of homeobox A9 and PBX homeobox 3 expression in
gastric cancer correlates with poor prognosis. Oncol Lett.
14:5883–5889. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Errico MC, Felicetti F, Bottero L, Mattia
G, Boe A, Felli N, Petrini M, Bellenghi M, Pandha HS, Calvaruso M,
et al: The abrogation of the HOXB7/PBX2 complex induces apoptosis
in melanoma through the miR-221&222-c-FOS pathway. Int J
Cancer. 133:879–892. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Han HB, Gu J, Ji DB, Li ZW, Zhang Y, Zhao
W, Wang LM and Zhang ZQ: PBX3 promotes migration and invasion of
colorectal cancer cells via activation of MAPK/ERK signaling
pathway. World J Gastroenterol. 20:18260–18270. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jung JG, Shih IM, Park JT, Gerry E, Kim
TH, Ayhan A, Handschuh K, Davidson B, Fader AN, Selleri L and Wang
TL: Ovarian cancer chemoresistance relies on the stem cell
reprogramming factor PBX1. Cancer Res. 76:6351–6361.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xu X, Cai N, Bao Z, You Y, Ji J and Liu N:
Silencing Pre-B-cell leukemia homeobox 3 decreases the
proliferation of human glioma cells in vitro and in vivo. J
Neurooncol. 135:453–463. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Aspland SE, Bendall HH and Murre C: The
role of E2A-PBX1 in leukemogenesis. Oncogene. 20:5708–5717.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rosales-Aviña JA, Torres-Flores J,
Aguilar-Lemarroy A, Gurrola-Díaz C, Hernández-Flores G,
Ortiz-Lazareno PC, Lerma-Díaz JM, de Celis R, González-Ramella Ó,
Barrera-Chaires E, et al: MEIS1, PREP1, and PBX4 are differentially
expressed in acute lymphoblastic leukemia: Association of MEIS1
expression with higher proliferation and chemotherapy resistance. J
Exp Clin Cancer Res. 30(112)2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xu X, Bao Z, Liu Y, Jiang K, Zhi T, Wang
D, Fan L, Liu N and Ji J: PBX3/MEK/ERK1/2/LIN28/let-7b positive
feedback loop enhances mesenchymal phenotype to promote
glioblastoma migration and invasion. J Exp Clin Cancer Res.
37(158)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ramberg H, Grytli HH, Nygård S, Wang W,
Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, et al:
PBX3 is a putative biomarker of aggressive prostate cancer. Int J
Cancer. 139:1810–1820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Alharbi RA, Pandha HS, Simpson GR,
Pettengell R, Poterlowicz K, Thompson A, Harrington K, El-Tanani M
and Morgan R: Inhibition of HOX/PBX dimer formation leads to
necroptosis in acute myeloid leukemia cells. Oncotarget.
8:89566–89579. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ramberg H, Alshbib A, Berge V, Svindland A
and Taskén KA: Regulation of PBX3 expression by androgen and Let-7d
in prostate cancer. Mol Cancer. 10(50)2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Dardaei L, Longobardi E and Blasi F: Prep1
and Meis1 competition for Pbx1 binding regulates protein stability
and tumorigenesis. Proc Natl Acad Sci USA. 111:E896–E905.
2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ando H, Natsume A, Senga T, Watanabe R,
Ito I, Ohno M, Iwami K, Ohka F, Motomura K, Kinjo S, et al:
Peptide-based inhibition of the HOXA9/PBX interaction retards the
growth of human meningioma. Cancer Chemother Pharmacol. 73:53–60.
2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lin HY, Zeng Liang YK, Wei XL and Chen CF:
GATA3 and TRPS1 are distinct biomarkers and prognostic factors in
breast cancer: Database mining for GATA family members in
malignancies. Oncotarget. 8:34750–34761. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jin Z, Xu L, Zhang L, Zhao M, Li D, Ye L,
Ma Y, Ren S, Yu H, Wang D, et al: Interleukin enhancer binding
factor 2 is a prognostic biomarker for breast cancer that also
predicts neoadjuvant chemotherapy responses. Am J Transl Res.
10:1677–1689. 2018.PubMed/NCBI
|
|
32
|
Lánczky A, Nagy Á, Bottai G, Munkácsy G,
Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to
validate survival-associated miRNAs utilizing expression data from
2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Finak G, Bertos N, Pepin F, Sadekova S,
Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu
A, et al: Stromal gene expression predicts clinical outcome in
breast cancer. Nat Med. 14:518–527. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Bild AH, Yao G, Chang JT, Wang Q, Potti A,
Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al:
Oncogenic pathway signatures in human cancers as a guide to
targeted therapies. Nature. 439:353–357. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Beck S, Sommer P, dos Santos Silva E, Blin
N and Gött P: Hepatocyte nuclear factor 3 (winged helix domain)
activates trefoil factor gene TFF1 through a binding motif adjacent
to the TATAA box. DNA Cell Biol. 18:157–164. 1999.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Bernardo GM, Lozada KL, Miedler JD,
Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE,
Kaestner KH, et al: FOXA1 is an essential determinant of ERalpha
expression and mammary ductal morphogenesis. Development.
137:2045–2054. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Farmer P, Bonnefoi H, Becette V,
Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J,
Cameron D, Goldstein D, et al: Identification of molecular apocrine
breast tumours by microarray analysis. Oncogene. 24:4660–4671.
2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Guo F, Kuo YF, Shih YCT, Giordano SH and
Berenson AB: Trends in breast cancer mortality by stage at
diagnosis among young women in the United States. Cancer.
124:3500–3509. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Baeyens-Fernández JA, Molina-Portillo E,
Pollan M, Rodríguez-Barranco M, Del Moral R, Arribas-Mir L,
Sánchez-Cantalejo Ramírez E and Sánchez MJ: Trends in incidence,
mortality and survival in women with breast cancer from 1985 to
2012 in Granada, Spain: A population-based study. BMC Cancer.
18(781)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dard A, Reboulet J, Jia Y, Bleicher F,
Duffraisse M, Vanaker JM, Forcet C and Merabet S: Human HOX
proteins use diverse and context-dependent motifs to interact with
TALE class cofactors. Cell Rep. 22:3058–3071. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Roux M and Zaffran S: Hox genes in
cardiovascular development and diseases. J Dev Biol. 4(pii:
E14)2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Parker HJ, Piccinelli P, Sauka-Spengler T,
Bronner M and Elgar G: Ancient Pbx-Hox signatures define hundreds
of vertebrate developmental enhancers. BMC Genomics.
12(637)2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Duque-Afonso J, Feng J, Scherer F, Lin CH,
Wong SH, Wang Z, Iwasaki M and Cleary ML: Comparative genomics
reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic
leukemia. J Clin Invest. 125:3667–3680. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Duque-Afonso J, Lin CH, Han K, Wei MC,
Feng J, Kurzer JH, Schneidawind C, Wong SH, Bassik MC and Cleary
ML: E2A-PBX1 remodels oncogenic signaling networks in B-cell
precursor acute lymphoid leukemia. Cancer Res. 76:6937–6949.
2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Liu Y, Xu X, Lin P, He Y, Zhang Y, Cao B,
Zhang Z, Sethi G, Liu J, Zhou X and Mao X: Inhibition of the
deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1)
degradation and thereby stimulates prostate cancer cell apoptosis.
J Biol Chem. 294:4572–4582. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Xu C, Li H, Zhang L, Jia T, Duan L and Lu
C: MicroRNA-1915-3p prevents the apoptosis of lung cancer cells by
downregulating DRG2 and PBX2. Mol Med Rep. 13:505–512.
2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Qiu Y, Wang ZL, Jin SQ, Pu YF, Toyosawa S,
Aozasa K and Morii E: Expression level of pre-B-cell leukemia
transcription factor 2 (PBX2) as a prognostic marker for gingival
squamous cell carcinoma. J Zhejiang Univ Sci B. 13:168–175.
2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Qiu Y, Morii E, Tomita Y, Zhang B,
Matsumura A, Kitaichi M, Okumura M and Aozasa K: Prognostic
significance of pre B cell leukemia transcription factor 2 (PBX2)
expression in non-small cell lung carcinoma. Cancer Sci.
100:1198–1209. 2009.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Qiu Z, Wang X, Shi Y and Da M: miR-129-5p
suppresses proliferation, migration, and induces apoptosis in
pancreatic cancer cells by targeting PBX3. Acta Biochim Biophys
Sin. (Shanghai 51):997–1007. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Li YS, Zou Y and Dai DQ: MicroRNA-320a
suppresses tumor progression by targeting PBX3 in gastric cancer
and is downregulated by DNA methylation. World J Gastrointest
Oncol. 11:842–856. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Li H, Wang J, Xu F, Wang L, Sun G, Wang J
and Yang Y: By downregulating PBX3, miR-526b suppresses the
epithelial-mesenchymal transition process in cervical cancer cells.
Future Oncol. 15:1577–1591. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Garcia-Cuellar MP, Steger J, Füller E,
Hetzner K and Slany RK: Pbx3 and Meis1 cooperate through multiple
mechanisms to support Hox-induced murine leukemia. Haematologica.
100:905–913. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Lamprecht S, Kaller M, Schmidt EM, Blaj C,
Schiergens TS, Engel J, Jung A, Hermeking H, Grünewald TGP,
Kirchner T and Horst D: PBX3 is part of an EMT regulatory network
and indicates poor outcome in colorectal cancer. Clin Cancer Res.
24:1974–1986. 2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Li H, Sun G, Liu C, Wang J, Jing R, Wang
J, Zhao X, Xu X and Yang Y: PBX3 is associated with proliferation
and poor prognosis in patients with cervical cancer. Onco Targets
Ther. 10:5685–5694. 2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Magnani L, Ballantyne EB, Zhang X and
Lupien M: PBX1 genomic pioneer function drives ERalpha signaling
underlying progression in breast cancer. PLoS Genet.
7(e1002368)2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Magnani L, Patten DK, Nguyen VT, Hong SP,
Steel JH, Patel N, Lombardo Y, Faronato M, Gomes AR, Woodley L, et
al: The pioneer factor PBX1 is a novel driver of metastatic
progression in ERα-positive breast cancer. Oncotarget.
6:21878–21891. 2015.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Costa RH, Grayson DR and Darnell JE Jr:
Multiple hepatocyte-enriched nuclear factors function in the
regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell
Biol. 9:1415–1425. 1989.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Hu Q, Luo Z, Xu T, Zhang JY, Zhu Y, Chen
WX, Zhong SL, Zhao JH and Tang JH: FOXA1: A promising prognostic
marker in breast cancer. Asian Pac J Cancer Prev. 15:11–16.
2014.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Yamaguchi N, Shibazaki M, Yamada C, Anzai
E, Morii M, Nakayama Y, Kuga T, Hashimoto Y, Tomonaga T and
Yamaguchi N: Tyrosine phosphorylation of the pioneer transcription
factor FoxA1 promotes activation of estrogen signaling. J Cell
Biochem. 118:1453–1461. 2017.PubMed/NCBI View Article : Google Scholar
|
